In conclusion, the anti-Lewis Y antibody, hu3S193, exhibited insufficient efficacy in patients with advanced hormone receptor-positive and Lewis-Y antigen-positive BC that progressed after ET was administered. Here, NR4A1 is linked to breast cancer.